Henrik Falhammar1,2, Jakob Skov3, Jan Calissendorff3,4, Jonatan D Lindh5, Buster Mannheimer6. 1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. henrik.falhammar@ki.se. 2. Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. henrik.falhammar@ki.se. 3. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. 4. Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital, Stockholm, Sweden. 5. Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden. 6. Department of Clinical Science and Education, Södersjukhuset AB, Karolinska Institutet, Stockholm, Sweden.
Abstract
CONTEXT: Glucose-lowering medications have occasionally been reported to cause hyponatremia, but the evidence is scarce. OBJECTIVES: To explore the association between glucose-lowering medications and severe hyponatremia. DESIGN, SETTING, AND PARTICIPANTS: Subjects hospitalized with a principal diagnosis of hyponatremia (n = 14,359) were compared with matched controls (n = 57,383). Data were derived by linkage of national population-based registers. Multivariable logistic regression adjusting for co-medication, diseases, previous hospitalizations, and socioeconomic factors was used to explore the association between hospitalization for hyponatremia and the use of different glucose-lowering medications. Furthermore, newly initiated (≤90 days) and ongoing use was investigated separately. MAIN OUTCOME MEASURES: Hospitalization due to hyponatremia. RESULTS: The unadjusted ORs (95% CI) for hospitalization due to hyponatremia were 1.41 (1.29-1.54) for insulins, 1.38 (1.27-1.50) for metformin, and 1.22 (1.07-1.38) for sulfonylureas. However, after adjustment for confounding factors the association was consistently reversed. Thus, for any glucose-lowering medication the adjusted OR was 0.63 (0.58-0.68). For insulins, metformin and sulfonylureas, adjusted ORs (95% CI) were 0.58 (0.52-0.65), 0.81 (0.72-0.90) and 0.81 (0.69-0.94), respectively. Odds ratios for newly initated medications were overall higher while those for ongoing treatment were further decreased. Thus, adjusted ORs (95% CI) for ongoing treatment with insulins, metformin, and sulfonylureas were 0.54 (0.48-0.61), 0.82 (0.73-0.91) and 0.78 (0.66-0.92). CONCLUSIONS: Glucose-lowering medications did not increase the risk for hospitalization due to severe hyponatremia. In fact, the association was inverse across all investigated drugs. The association may be mediated by pharmacologic mechanisms, but the uniform effects across drug-classes suggest properties of the diabetic disease are of importance.
CONTEXT: Glucose-lowering medications have occasionally been reported to cause hyponatremia, but the evidence is scarce. OBJECTIVES: To explore the association between glucose-lowering medications and severe hyponatremia. DESIGN, SETTING, AND PARTICIPANTS: Subjects hospitalized with a principal diagnosis of hyponatremia (n = 14,359) were compared with matched controls (n = 57,383). Data were derived by linkage of national population-based registers. Multivariable logistic regression adjusting for co-medication, diseases, previous hospitalizations, and socioeconomic factors was used to explore the association between hospitalization for hyponatremia and the use of different glucose-lowering medications. Furthermore, newly initiated (≤90 days) and ongoing use was investigated separately. MAIN OUTCOME MEASURES: Hospitalization due to hyponatremia. RESULTS: The unadjusted ORs (95% CI) for hospitalization due to hyponatremia were 1.41 (1.29-1.54) for insulins, 1.38 (1.27-1.50) for metformin, and 1.22 (1.07-1.38) for sulfonylureas. However, after adjustment for confounding factors the association was consistently reversed. Thus, for any glucose-lowering medication the adjusted OR was 0.63 (0.58-0.68). For insulins, metformin and sulfonylureas, adjusted ORs (95% CI) were 0.58 (0.52-0.65), 0.81 (0.72-0.90) and 0.81 (0.69-0.94), respectively. Odds ratios for newly initated medications were overall higher while those for ongoing treatment were further decreased. Thus, adjusted ORs (95% CI) for ongoing treatment with insulins, metformin, and sulfonylureas were 0.54 (0.48-0.61), 0.82 (0.73-0.91) and 0.78 (0.66-0.92). CONCLUSIONS:Glucose-lowering medications did not increase the risk for hospitalization due to severe hyponatremia. In fact, the association was inverse across all investigated drugs. The association may be mediated by pharmacologic mechanisms, but the uniform effects across drug-classes suggest properties of the diabetic disease are of importance.
Authors: Joseph G Verbalis; Steven R Goldsmith; Arthur Greenberg; Cynthia Korzelius; Robert W Schrier; Richard H Sterns; Christopher J Thompson Journal: Am J Med Date: 2013-10 Impact factor: 4.965
Authors: Nicole Nigro; Bettina Winzeler; Isabelle Suter-Widmer; Philipp Schuetz; Birsen Arici; Martina Bally; Claudine Blum; Roland Bingisser; Andreas Bock; Andreas Huber; Beat Müller; Christian H Nickel; Mirjam Christ-Crain Journal: J Am Geriatr Soc Date: 2015-03-04 Impact factor: 5.562
Authors: Jonatan D Lindh; David Nathanson; Buster Mannheimer; Jakob Skov; Henrik Falhammar; Jan Calissendorff Journal: Endocrine Date: 2019-09-02 Impact factor: 3.633
Authors: Katja Biering Leth-Møller; Annette Højmann Hansen; Maia Torstensson; Stig Ejdrup Andersen; Lars Ødum; Gunnar Gislasson; Christian Torp-Pedersen; Ellen Astrid Holm Journal: BMJ Open Date: 2016-05-18 Impact factor: 2.692
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; Jonatan D Lindh; Buster Mannheimer Journal: J Psychopharmacol Date: 2020-07-20 Impact factor: 4.153
Authors: Henrik Falhammar; Jakob Skov; Jan Calissendorff; David Nathanson; Jonatan D Lindh; Buster Mannheimer Journal: J Clin Endocrinol Metab Date: 2020-10-01 Impact factor: 5.958